Open AccessProgression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center and validation in the Memorial Sloan Kettering Cancer Center Cohort.
Author(s) -
Hongnan Mo,
Bo Xu,
Fei Ma,
Qing Li,
Pin Zhang,
Peng Yuan,
Jiayu Wang,
Yang Luo,
Rong Cai,
Qiao Li,
Yiqun Li,
Xiuwen Guan,
Shaoyan Lin,
Yimeng Chen,
Zijing Wang
Publication year - 2019
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2019.5.suppl.88
Subject(s) - medicine , breast cancer , cohort , cancer , oncology , progression free survival , metastatic breast cancer , stage (stratigraphy) , overall survival , paleontology , biology
88 Background: Breast cancer is a clinically heterogeneous disease. The aim of our study was to evaluate the effect of progression-free survival (PFS) in predicting overall survival (OS), and to explore whether PFS in the first-line treatment could help in the choice of posterior regimens. Methods: Data from the China National Cancer Center database that recorded 2061 women from February 1992 to March 2018 were pooled as the study cohort. Women were eligible if they had metastatic breast cancer and had not received systemic treatment for the advanced disease. The independent validation cohort was composed of 1756 patients with advanced breast cancer from the Memorial Sloan Kettering Cancer Center. Results: The correlation coefficient between PFS and OS was 0.862 in patients receiving endocrine therapy alone as first-line treatment, and 0.647 in the whole study cohort (all P 12m, but not in patients with first-line PFS < 12m (P = 0.109).A similar pattern is observed in the validation cohort. Conclusions: First-line PFS at 12 months predicted OS in patients with advanced breast cancer, and could potentially serve as a convenient identifier in clinical practice to precision medicine approach.